Educational Module

Educational Module 2 – Hypertrophic cardiomyopathy patients over time: what are they at risk of and why?

Course Overview

This content was accurate at the time of release, 1 November 2021. Accreditation for this course expired on 2 November 2022. If you would still like an activity completion certificate, send your request to [email protected].

This online learning module is designed to raise awareness for HCM and provide you with an understanding of how HCM progresses over time and the associated mortality. It assists clinicians in community practice or those with an interest in HCM management to:

  • understand HCM natural history
  • correctly assign hemodynamic category
  • provide appropriate management strategies for heart failure symptoms
  • provide regular screening of asymptomatic patients
  • implement strategies for sudden death prevention
  • know when referral to an HCM expert center is appropriate

This online learning module is designed to be completed in 60 minutes.

Target audience

Family/general physicians, general/community cardiologists, cardiac nurses, pediatricians, pediatric nurses, genetic counselors

Funding disclosure

This activity is supported by educational grant funding from Bristol Myers Squibb, Cytokinetics and Sanofi. Learners may participate in this educational activity free of charge.

  • Natural history of hypertrophic cardiomyopathy
  • Asymptomatic patients
  • Heart failure symptoms
  • Atrial fibrillation
  • Risk of sudden death

By the end of this activity, attendees will be able to:

  • Explain why early diagnosis of hypertrophic cardiomyopathy (HCM) potentially improves the natural history of HCM patients
  • Outline management strategies for asymptomatic patients and apply these to example patients
  • Recount heart failure symptoms in HCM patients
  • Recall how and why atrial fibrillation manifests in HCM
  • List the major noninvasive risk factors to identify HCM patients at high risk for sudden death and interpret these in the stratification of an example patient

Accreditation for this course has expired. You may view the program, but CME / CE is no longer available and no certificate will be issued.

Dr John Lynn Jefferies, MD, Professor and Chief of Advanced Heart Failure and Transplant Cardiology, Cardiovascular Disease, Methodist University Hospital/ University of Tennessee, St Jude Children’s Research Hospital, has received financial compensation for consulting for Abbott, Novartis, and Pfizer, and received research grants from Myokardia, Abbott, Novartis, and Pfizer.

Dr Anjali Tiku Owens, MD, Medical Director of the Advanced Heart Failure and Transplant Cardiology, Penn Center for Inherited Cardiovascular Disease/ University of Pennsylvania, received financial compensation for consulting for MyoKardia/BMS and Cytokinetics.

Disclosure of educational planners:

Lauren Tebay, BA (mod), PhD, Senior Medical Writer, PCM Scientific, has no relevant conflicts of interest to disclose.

Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant conflicts of interest to disclose.

All relevant financial relationships have been mitigated.